Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.50 |
| ▸ | RORC | P51449 | 7/20 | 0.49 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13771539 | 1.00 | TSHR (0.52) | TSHRALOX15ATMUSP30RORC | |
| SCHEMBL31513766 | 0.92 | TSHR (0.47) | TSHRALOX15ATMUSP30RORC | |
| SCHEMBL6982730 | 0.92 | TSHR (0.47) | TSHRALOX15ATMUSP30RORC | |
| SCHEMBL240381 | 0.92 | TSHR (0.57) | TSHRALOX15ATMUSP30RORC | |
| SCHEMBL1309072 | 0.88 | RORC (0.51) | TSHRALOX15ATMRORCTACR1 | |
| SCHEMBL3545555 | 0.86 | RORC (0.54) | RORC | |
| SCHEMBL348952 | 0.86 | CYP11B2 (0.47) | USP30RORCSCD5OPRD1OPRK1 | |
| SCHEMBL3695939 | 0.86 | RORC (0.54) | TSHRALOX15USP30RORCSCD5 | |
| SCHEMBL15595091 | 0.86 | TSHR (0.53) | TSHRALOX15ATMTACR1OPRD1 | |
| SCHEMBL655150 | 0.86 | DRD2 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233077-B1 | DOPAMINE D2 RECEPTOR LIGANDS | BROAD INST INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12441726-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-12428373-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| CN-115297861-B | Compounds and uses thereof | 福宏治疗公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4096667-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| US-11498896-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2022-11-15 | — | — | US | disclosed |
| CN-115297861-A | Compound and use thereof | 福宏治疗公司 | 2022-11-04 | — | — | CN | disclosed |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | LNCYTE CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| US-7304081-B2 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-20070179142-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-08-02 | — | — | US | disclosed |
| EP-1756063-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-02-28 | — | — | EP | disclosed |
| CN-1898234-A | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORP (US) | 2007-01-17 | — | — | CN | disclosed |
| EP-1678167-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | Incyte Corporation (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050282858-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-22 | — | — | US | disclosed |
| WO-2005110992-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION | 2005-05-26 | — | — | US | disclosed |
| WO-2005037826-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11498896-B2 | Dopamine D2 receptor ligands | DRD2, SLC6A3, NTSR2 | TSHR 126/4885ALOX15 2824/4885ATM 4111/4885 |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | DRD2, SLC6A3, NTSR2 | TSHR 126/4885ALOX15 2824/4885ATM 4111/4885 |
| US-12441726-B2 | Compounds and uses thereof | VHL, CLN6, TFEB | TSHR 4351/4885ALOX15 3537/4885ATM 1525/4885 |
| US-12428373-B2 | Dopamine D2 receptor ligands | DRD2, SLC6A3, NTSR2 | TSHR 126/4885ALOX15 2824/4885ATM 4111/4885 |
| US-20050282858-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | TSHR 328/4885ALOX15 106/4885ATM 4439/4885 |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | TSHR 4351/4885ALOX15 3537/4885ATM 1525/4885 |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | MMP25, MMP9, MMP24 | TSHR 2962/4885ALOX15 346/4885ATM 4591/4885 |
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | MMP25, MMP2, MMP14 | TSHR 3634/4885ALOX15 642/4885ATM 4580/4885 |
| US-20070179142-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | TSHR 328/4885ALOX15 106/4885ATM 4439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.